CurrentBlue Cross Blue Shield - TexasPolicy CPCPLABOSO

Urine Culture Testing for Bacteria

Customize your policy alerts

Sign up for Blue Cross Blue Shield - Texas Policy CPCPLABOSO alerts

Get alerted when Policy CPCPLABOSO changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy governing reimbursement and clinical coverage criteria for urine culture testing (including isolate identification and antibiotic susceptibilities) for Blue Cross and Blue Shield of Texas members; affects ordering providers and laboratories performing urine cultures.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyUrine Culture Testing for Bacteria

Policy CodePolicy CPCPLABOSO

Change TypeNew policy (established)

Effective DateJan 1, 2025

Last ReviewSep 13, 2024

Next Review Date

Key ActionReview plan documents for product-specific coverage and prior authorization requirements and submit clinical documentation supporting medical necessity when ordering urine culture testing.

SourceLink

POLICY UPDATE CHANGES

New policy establishing lab management reimbursement criteria for urine culture testing.

1.0

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue Cross Blue Shield - TexasPolicy CPCPLABOSO

Urine Culture Testing for Bacteria

Customize your policy alerts

Sign up for Blue Cross Blue Shield - Texas Policy CPCPLABOSO alerts

Get alerted when Policy CPCPLABOSO changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyUrine Culture Testing for Bacteria

Policy CodePolicy CPCPLABOSO

Change TypeNew policy (established)

Effective DateJan 1, 2025

Last ReviewSep 13, 2024

Next Review Date

Key ActionReview plan documents for product-specific coverage and prior authorization requirements and submit clinical documentation supporting medical necessity when ordering urine culture testing.

SourceLink

POLICY UPDATE CHANGES

New policy establishing lab management reimbursement criteria for urine culture testing.

1.0

Coverage Criteria for Urine Culture Testing

Reimbursable indications and non-reimbursable situations

Urine culture testing (with isolate identification and antibiotic susceptibilities if applicable) may be reimbursed when any of the following specific situations apply; otherwise it is not reimbursable.

Reimbursable situations: Pregnant individuals; Asymptomatic individuals undergoing urological interventions which breach the mucosa (pre-procedure); Individuals exhibiting at least one sign or symptom of possible UTI or bacteriuria (see Note 1); To assess pyelonephritis; Other specified exceptions per plan or pathogen panel guidance; When isolate identification and antibiotic susceptibilities are applicable.

See Note 1 for signs/symptoms list

Non-reimbursable situations: For all other instances of asymptomatic urinary tract infection or asymptomatic bacteriuria not described above, urine culture testing (with isolate identification and antibiotic susceptibilities if applicable) is not reimbursable; Follow-up urine culture testing for an uncomplicated urinary tract infection in individuals who show evidence of clinical resolution is not reimbursable; Urine culture testing is not reimbursable as part of assessment or prognosis of prostate biopsy or as part of initial screening for asymptomatic prostatitis.

Urine culture testing (including isolate identification and antibiotic susceptibilities when applicable) is not reimbursable for routine evaluation of asymptomatic bacteriuria except where specific exceptions apply. Permitted exceptions include testing for pregnant individuals and for asymptomatic patients undergoing urological interventions that breach the mucosa when performed prior to the procedure. Additionally, urine culture is allowed when an individual is exhibiting at least one recognized sign or symptom of urinary tract infection or bacteriuria (see Note 1) or when assessing suspected pyelonephritis. Testing performed solely as part of prostate biopsy assessment or as initial screening for asymptomatic prostatitis is explicitly not reimbursable.

Follow-up urine culture testing after completion of therapy for an uncomplicated urinary tract infection is considered not reimbursable when the individual shows evidence of clinical resolution. In other words, routine post-treatment cultures for uncomplicated UTI are not covered unless a different covered indication or clinical concern is documented (for example persistent or recurrent symptoms or another exception described in this policy).

Specific Covered Indications

Pregnancy

Covered when ALL of the following are met:

Pregnancy: Individual is pregnant and urine culture testing (with isolate identification and antibiotic susceptibilities if applicable) is ordered to evaluate for urinary tract infection.

Refer to pathogen panel guidance CPCPLABO4S as needed

Pre-procedural testing for urological interventions that breach mucosa

Covered when ANY of the following pre-procedural conditions apply:

Pre-procedural testing for urological interventions that breach mucosa: Asymptomatic individual is scheduled for a urological intervention which will breach the mucosa and urine culture testing (with isolate identification and antibiotic susceptibilities if applicable) is ordered prior to the procedure.

Pre-procedure testing applies to interventions that breach the mucosa; check plan-specific prior authorization requirements

Procedure and Billing Codes

Procedure codes referencedmixed

87077
87086
87088
87140
87147
87149
87181
87186

Provider Responsibilities and Billing Guidance

Prior Authorization

Prior Authorization — Verify Plan Rules

Check member's plan documents and product-specific rules for prior authorization requirements before ordering tests. Prior authorization rules may vary by product and eligibility; when in doubt, verify with the member's benefit booklet or plan administrator.

Plan documents may supersede policy language for coverage determinations
See product-specific prior authorization rules for lab management and pathogen panel testing

Step Therapy

Step Therapy — None Specified in This Policy

There are no specific step therapy requirements stated in this policy for urine culture or pathogen panel testing. Providers should still follow any step therapy rules that may appear in the member's plan documents.

No step therapy requirements specified in CPCPLABOSO policy
Confirm any plan-level step therapy requirements prior to service

Ordering Requirements

Note

Review coverage and support orders with clinical information

Before ordering, review product-specific coverage and prior authorization rules in the member's plan documents; ensure orders are supported by clinical documentation of symptoms or eligible indications (e.g., pregnancy, pre‑procedural testing, signs/symptoms of UTI, or assessment of pyelonephritis).

Document at least one eligible indication or relevant clinical sign/symptom when ordering (see policy Note 1 for signs/symptoms list).
Confirm any required prior authorization or plan-specific restrictions prior to testing.

Not Covered / Exclusions

NOT COVERED: Routine urine culture testing for asymptomatic bacteriuria (except for the specified exceptions such as pregnancy or pre-procedural testing for interventions that breach the mucosa) is not reimbursable. Also not covered are follow-up urine cultures after clinical resolution of an uncomplicated UTI, urine culture performed as part of assessment or prognosis for prostate biopsy, and urine culture used solely for initial screening of asymptomatic prostatitis.

Frequency and Follow-up Limits

Follow-up urine culture after uncomplicated UTI

Policy frequency ruleFollow-up urine culture testing after clinical resolution of an uncomplicated urinary tract infection is not reimbursable.

Clinical contextApplies to individuals who show evidence of clinical resolution of infection (post-treatment).

ScopeApplies to urine culture testing with isolate identification and antibiotic susceptibilities when performed solely as a follow-up after uncomplicated UTI resolution.

Exception noteThis restriction does not alter reimbursable indications listed elsewhere (e.g., pregnancy, pre-procedural testing, symptomatic individuals, or assessment of pyelonephritis).

Definitions and Signs/Symptoms

Signs and symptoms of UTI used in criteria

FeverFever

DysuriaDysuria (painful urination)

Urgency/frequencyUrgency to urinate or increased frequency of urination

Suprapubic or flank painSuprapubic tenderness or lower back/side (flank) pain

Urinalysis abnormalitiesPyuria, hematuria, cloudy urine, or other abnormal urinalysis findings

Systemic/GI symptomsNausea, vomiting, chills, night sweats — consider in pyelonephritis assessment

Most actionable signPresence of at least one sign or symptom of possible UTI/bacteriuria (see list) — qualifies patient for urine culture reimbursement when present.

Background

Urine culture is used to detect and identify bacterial pathogens responsible for urinary tract infection and to guide antibiotic susceptibility testing. Clinical guidance within this policy limits routine culture to situations where results will affect management — for example, symptomatic patients, pregnant individuals, pre-procedural screening for urological interventions that breach the mucosa, or when evaluating suspected pyelonephritis. The policy aligns with the principle of avoiding unnecessary testing and treatment of asymptomatic bacteriuria unless a covered exception applies.

Revision History

2024-09-13Policy approval and creationLatest

Policy CPCPLABOSO was created and approved on 09/13/2024 (Version 1.0).

2025-01-01Plan effective date

Policy CPCPLABOSO becomes effective for Blue Cross and Blue Shield of Texas on 01/01/2025.